Kyverna Therapeutics
KYTX
99 hedge funds and large institutions have $321M invested in Kyverna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 9 closing their positions.
300% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 9
135% more capital invested
Capital invested by funds: $136M → $321M (+$184M)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
38% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 21
32% more funds holding
Funds holding: 75 → 99 (+24)
25.45% more ownership
Funds ownership: 52.48% → 77.93% (+25%)
19% less call options, than puts
Call options by funds: $967K | Put options by funds: $1.19M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$14.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$12.4M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$11.1M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.28M |
| 5 |
Morgan Stanley
New York
|
+$6.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$4.07M |
| 2 |
CCM
Catalio Capital Management
New York
|
-$3.52M |
| 3 |
KCP
Kera Capital Partners
San Jose,
California
|
-$2.15M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.92M |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
101
Catalio Capital Management
New York
| – | -$3.52M | -586,909 | Closed |
|
|
PCM
102
Prelude Capital Management
New York
| – | -$117K | -19,438 | Closed |
|
|
TI
103
Trexquant Investment
Stamford,
Connecticut
| – | -$90.7K | -15,109 | Closed |
|
104
AQR Capital Management
Greenwich,
Connecticut
| – | -$81.3K | -13,542 | Closed |
|
105
Ameriprise
Minneapolis,
Minnesota
| – | -$77.3K | -12,882 | Closed |
|
106
Ohio Public Employees Retirement System (OPERS)
Columbus,
Ohio
| – | -$27.6K | -4,600 | Closed |
|
|
ASN
107
Advisory Services Network
Atlanta,
Georgia
| – | -$516 | -86 | Closed |
|
|
IA
108
IFP Advisors
Tampa,
Florida
| – | -$96 | -16 | Closed |
|
KYTX Hedge Fund Activity: Q4 2025 in Review
99 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2025, worth a combined $321M — up 135% from $136M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new KYTX positions and 9 closed out — a net gain of 27 holders — while 29 added to existing stakes and 21 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.07M sold.
- 99 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2025, up from 75 in Q3 2025.
- Funds reported $321M of Kyverna Therapeutics stock for Q4 2025, up 135% quarter-over-quarter.
- 36 funds opened new Kyverna Therapeutics positions in Q4 2025 and 9 closed out, a net change of +27 holders.
- The largest Kyverna Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $14.8M added.
- The largest Kyverna Therapeutics seller in Q4 2025 was Franklin Resources, an estimated $4.07M sold.
Based on aggregated 13F filings for Q4 2025.